Potential alterations in immunogenicity by combining or simultaneously administering vaccine components.
about
Immunogenicity of a multi-component recombinant human acrosomal protein vaccine in female Macaca fascicularis.Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys.Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model systemCombined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein.Combination vaccines: defining and addressing current safety concerns.Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogenHsp110-mediated enhancement of CD4+ T cell responses to the envelope glycoprotein of members of the family Flaviviridae in vitro does not occur in vivoCurrent state of pneumococcal vaccines.Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditionsImmunogenicity of Mannheimia haemolytica recombinant outer membrane proteins serotype 1-specific antigen, OmpA, OmpP2, and OmpD15Adsorption of Toll-Like Receptor 4 Agonist to Alum-Based Tetanus Toxoid Vaccine Dampens Pro-T Helper 2 Activities and Enhances Antibody Responses.PEDIARIX: clinical trials.Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates.Interactions of conjugate vaccines and co-administered vaccinesSafety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.Surveillance of adverse effects following vaccination and safety of immunization programs.Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.Cyclopeptide scaffolds in carbohydrate-based synthetic vaccines.Tetanus-diphtheria-pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial⋆.Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier.Simulating Immune Interference on the Effect of a Bivalent Glycoconjugate Vaccine against Haemophilus influenzae Serotypes "a" and "b".Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response.Antigen-specific immunotherapy and influenza vaccination in type 1 diabetes: timing is everything.Combination Vaccines.
P2860
Q29394992-9DCCFDBF-2F02-4484-878D-68668AAF5EABQ33753799-B66507BF-6EB4-430E-8909-BD07A284FEDFQ33834916-7B64CF66-046B-4C78-B707-FA7B2BE56036Q33909096-4D6885BB-56B0-41F4-B2C5-600D3783ABC0Q34034071-DC3FB700-5C85-4192-948F-056DF1A9AC33Q34440127-6CD9DA06-8429-4BA3-BBD5-98A09E19772AQ34717906-B7445AF4-4323-4943-AB56-DC6CA60556B3Q34738862-DB9353D9-64D3-4F7A-9129-56794147263EQ34744239-7C9FB402-4D79-4056-80C5-FC9789C72C44Q35061547-B9E25C65-025C-40F4-A409-D1BC969CEE93Q35598191-AE63043E-6564-42B2-9184-6E68E009A373Q36035019-95BEBBDA-149C-4A04-A42B-FCBE7402F6D4Q36124930-F9E42468-B183-48B4-BABA-606B0CC538D6Q37077660-83D04966-B655-4174-A727-3D3B13BA3F6DQ37130164-4AD8E8AC-6641-4C2A-8709-24BB2B23BFB5Q37130813-CF15157E-6223-4305-A8BC-F5F7F19CBEAAQ37622887-DC213851-ACCB-4646-89D2-484FCBB0F01AQ37823382-B37A4829-45F5-4AC7-92E4-131E5C7FC960Q38611378-13EA3101-13F1-45F1-B703-3552CFECCED2Q39169715-94D803B0-0011-496F-BEC9-6D3518CF404EQ40265484-622C5B82-26FF-4FF5-90AB-CA0B4D6A6A9EQ40533459-AEB65AD4-B43E-4E1A-94D1-851D5BC04CF4Q40629252-1CD2A985-6F57-4041-9591-3BAE143A1BE4Q41812746-2811E279-1956-47AA-8FDD-D867D3AD5E84Q54311826-6C18E4E1-A97C-4695-AEEE-2FD8B933A63BQ54857966-DBDDEF28-EF4C-407B-A559-6F393E20A9F8
P2860
Potential alterations in immunogenicity by combining or simultaneously administering vaccine components.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Potential alterations in immun ...... inistering vaccine components.
@en
type
label
Potential alterations in immun ...... inistering vaccine components.
@en
prefLabel
Potential alterations in immun ...... inistering vaccine components.
@en
P2860
P1476
Potential alterations in immun ...... inistering vaccine components.
@en
P2093
P2860
P356
10.1111/J.1749-6632.1995.TB44436.X
P407
P577
1995-05-01T00:00:00Z